Roche Holding AG (XSWX:RO) Cash Receipts from Operating Activities

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RO Roche Holding AG XSWX:RO
74 GF Score
Price CHF366.00
GF Value CHF271.76
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.

XSWX:RO
74GF Score
Roche Holding AG XSWX:RO
Cash Receipts from Operating Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF366.00 is trading 34.7% above its estimated GF Value™ of CHF271.76. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for XSWX:RO:

  • Cash Receipts from Operating Activities:
  • GF Value™: CHF271.76 vs. price of CHF366.00 (34.7% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
74GF Score

Get the complete analysis for XSWX:RO

Cash Receipts from Operating Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF366.00
Price
CHF271.76
GF Value